IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin

IRADIMED just reminded investors that strong medical device stories can still sting in the short term. The stock fell 4.6% to US$90.86 into the close, even as the company posted Q2 revenue of US$20.5m and non GAAP earnings per share of US$0.46. The headline this quarter is not the top line or the earnings line. It is the deliberate hit to gross margin as the new 3870 MR intravenous pump moves from expensive early production into what management describes as a higher volume, more efficient phase.

Is IRADIMED’s 49.2x P/E a growth story that justifies a premium tag, or is the stock leaning into overpay territory at US$90.86? Compare market optimism against the full valuation workup on our valuation analysis for IRADIMED.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$20.5m vs. US$20.4m (approximately flat, with a slight increase of about 0.5%)
• Net Income, Excl. Extra Items (Q2 2026 vs. Q2 2025): US$5.9m vs. US$5.8m (stable, with a modest increase of about 1%)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.46 vs. US$0.45 (a small uplift of roughly 1% to 2%)
• Gross Margin (Q2 2026 vs. Q2 2025): 74% vs. 78% (compressed by about 4 percentage points, primarily due to early 3870 MR IV pump ramp costs)

Tired of scrolling through long stretches of earnings commentary and raw figures? Get a clear visual snapshot of how IRADIMED’s valuation, growth metrics and recent performance fit together in the full company report for IRADIMED.

IRADIMED bull case rests on 3870 execution

Bulls argue IRADIMED is a high quality niche medical device company where the 3870 pump triggers a multi year replacement and conversion cycle, lifting both growth and margins. Q2 shows some key milestones hit. Management moved from zero to roughly 130 general release 3870 units, which matches internal build targets, and bookings ran at more than double shipments, which supports the view that demand is real rather than marketing hype. Recurring revenue drivers such as disposables and maintenance grew in the mid double digits, and quad 3870 configurations now represent about 70% of replacements, with average selling prices north of US$110,000. That mix shift is consistent with the thesis that each customer becomes more valuable over time. The trade off is a 4 percentage point hit to gross margin to 74%, which means the margin uplift part of the bull story is not yet validated by current reported numbers.

IRADIMED bear case focuses on margin risk

Bears worry IRADIMED is concentrated in a narrow MRI compatible product set, that the 3870 ramp could be bumpy, and that profitability might be peaking rather than building. Q2 offers some support to those concerns. Headline revenue was roughly flat at US$20.5m and gross margin slipped from 78% to 74% as early 3870 production soaked up extra labor and overhead. That is exactly the type of margin compression skeptics flag for a single product ramp. The stock reaction also leaned their way, with the price falling about 4.6% on the day and returns down over the past month. At the same time, execution risks are not yet playing out as a demand problem. Bookings outpaced shipments and guidance for Q3 and full year 2026 was reaffirmed, which counters fears of an immediate slowdown or order cancellations.

After a flat revenue quarter and a 4 percentage point squeeze in gross margin on the 3870 ramp, it is fair to ask whether IRADIMED’s execution and insider selling trends hint at deeper issues or one off growing pains. Review the structured warning scorecard and see what the risk analysis for IRADIMED which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If IRADIMED’s steady Q2 revenue and margin squeeze on the 3870 ramp have your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the story develops. When you decide to take or adjust a position, keep on top of what matters with the Portfolio Command Center that cuts through noise and highlights key changes to your holdings. For longer term conviction, compare your view on IRADIMED with thousands of other investors through the Community and see which risks and opportunities others are focusing on. By spotting hidden catalysts and potential red flags early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond IRADIMED?

Fresh stock ideas get picked over fast. Some are building quiet breakout momentum while others stay under the radar for now. Check them while it matters and get in early.

• Spot potential breakout stories with strong balance sheets before the crowd by scanning this curated list of solid balance sheet and fundamentals stocks (45 results).
• Target companies leaning into AI trends with real businesses behind them using the hand picked 70 profitable AI stocks that aren't just burning cash.
• Zero in on income opportunities that aim to keep cash flows flying with a focused shortlist of 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com